Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Dow
Express Scripts
McKinsey
Baxter

Last Updated: October 6, 2022

Details for Patent: 8,853,156


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,853,156 protect, and when does it expire?

Patent 8,853,156 protects TRADJENTA and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: 8,853,156
Title:Treatment for diabetes in patients inappropriate for metformin therapy
Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
Inventor(s): Dugi; Klaus (Dresden, DE), Graefe-Mody; Eva Ulrike (Biberach, DE), Harper; Ruth (Reading, GB), Woerle; Hans-Juergen (Munich, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:13/057,295
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,853,156
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,853,156

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim TRADJENTA linagliptin TABLET;ORAL 201280-001 May 2, 2011 AB RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,853,156

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08161989Aug 7, 2008
08166827Oct 16, 2008
PCT Information
PCT FiledAugust 05, 2009PCT Application Number:PCT/EP2009/060170
PCT Publication Date:February 11, 2010PCT Publication Number: WO2010/015664

International Family Members for US Patent 8,853,156

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072920 See Plans and Pricing
Australia 2009279085 See Plans and Pricing
Brazil PI0916997 See Plans and Pricing
Canada 2732803 See Plans and Pricing
Chile 2011000259 See Plans and Pricing
China 102105145 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Baxter
Boehringer Ingelheim
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.